Clinical Trials Logo

Clinical Trial Summary

Primary Objectives: Part 1: to confirm the recommended tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma population Part 2: to assess the antitumor activity of tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or GEJ adenocarcinoma Secondary Objectives: - To assess safety - To assess durability - To assess progression-free survival (PFS) - To assess the disease control rate (DCR) - To assess the pharmacokinetics (PK) - To assess the immunogenicity


Clinical Trial Description

34 weeks (up to 4 weeks for screening, a median of 18 weeks for treatment, and a median of 12 weeks for end-of-treatment assessments and the safety follow-up visit). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05071053
Study type Interventional
Source Sanofi
Contact email recommended (Toll free number for US & Canada)
Phone 800-633-1610
Email [email protected]
Status Recruiting
Phase Phase 2
Start date October 15, 2021
Completion date January 3, 2023

See also
  Status Clinical Trial Phase
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Withdrawn NCT02274012 - Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment Phase 2
Completed NCT01980394 - Esophageal Stump Washout N/A
Terminated NCT01365130 - Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen Phase 2
Recruiting NCT02884453 - Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma Phase 2
Active, not recruiting NCT03416244 - A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer Phase 2
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A